Breathing new life into metastatic NSCLC: Innovations that are Lung-ing Ahead - Focus on ALK and ADCs

We would like to hear your feedback. Please share here . Despite remarkable strides in ALK-targeted therapies, challenges such as resistance and progression remain prominent in metastatic non-small cell lung cancer (NSCLC). Third-generation TKIs have reshaped survivorship, yet disease evolution demands deeper clinical insight and next-generation strategies.

Antibody-Drug Conjugates (ADCs) are also emerging as promising contenders in addressing unmet needs in NSCLC. To delve into these advancements, Docplexus, in association with Pfizer and Indian Society of Medical and Pediatric Oncology ( ISMPO) , presents a high-impact virtual event – Oncosummit: Lung Cancer 2025 , on Saturday , 5th July 2025 , from 4:00 PM to 6:30 PM IST . Join our esteemed national and international faculty as they explore: Latest evidence on 3rd gen TKIs in ALK+ NSCLC Mechanisms of resistance and strategic…